Sunovion Pharmaceuticals Inc., which use to be Sepracor, announced that its schizophrenia treatment drug Latuda has begun selling in pharmacies across America.
The U.S. Food & Drug Administration approved Latuda in October, 2010 after four six-week placebo-controlled studies.
Saburo Hamanaka, chairman and CEO of the company, called the drug a “leading product for our company.”
Sunovion also developed Lunesta, the insomnia treatment drug.
Sunovion is the U.S. subsidiary of Dianippon Sumitoro Pharmaceuticals, which is based in Japan. DSP purchased Marlborough-based Sepracor in September 2009. In July, the company dropped the Sepracor name and it is now referred to as Sunovion. Read about the company’s transition here.
ADVERTISEMENT
Read more
